# Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

Study · id `cardio:ct-nct05065216` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05065216](<https://clinicaltrials.gov/study/NCT05065216>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05065216

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 728 participants.

## Technical summary

Registry record NCT05065216. Randomized; double masking; primary purpose treatment. Start 2021-11-07 (actual); primary completion 2026-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 728 participants (planned count; ClinicalTrials.gov record NCT05065216, source copy `cardio:ctgov-nct05065216-2026-09-14`, retrieved 2026-10-26)
- Started: 2021-11-07 (actual) (ClinicalTrials.gov record NCT05065216, source copy `cardio:ctgov-nct05065216-2026-09-14`, retrieved 2026-10-26)
- Primary completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT05065216, source copy `cardio:ctgov-nct05065216-2026-09-14`, retrieved 2026-10-26)
- Completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT05065216, source copy `cardio:ctgov-nct05065216-2026-09-14`, retrieved 2026-10-26)
- Countries: United States; Belgium; Canada; France; Georgia; Hungary; Poland; Romania; Spain; United Kingdom (ClinicalTrials.gov record NCT05065216, source copy `cardio:ctgov-nct05065216-2026-09-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05065216-2026-09-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
- Acronym: ReMEDy2
- Condition: Acute Stroke
- Condition: Ischemic Stroke
- Condition: Stroke
- Intervention (Drug): Recombinant human tissue kallikrein
- Intervention (Other): Placebo for DM199 Solution for Injection
- Lead sponsor: DiaMedica Therapeutics Inc
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)

## Provenance

Content hash: 9b283a4fe21e76eca0fb72a72af064daad330d1974bd5b68ac284abd6370f0f9
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
